Your browser doesn't support javascript.
loading
Perioperative Changes and Progress in Photoselective Vaporization of the Prostate with GreenLight XPS 180 W System: A Single Center Experience.
Reimann, Maximilian; Fishman, Nikita; Almedom, Zenai; Lichy, Isabel; Buckendahl, John; Steiner, Ursula; Friedersdorff, Frank; Busch, Jonas; Fuller, Tom Florian; Miller, Kurt; Hinz, Stefan; Cash, Hannes.
Afiliación
  • Reimann M; Department of Urology, Charité - University Medicine Berlin, Berlin, Germany.
  • Fishman N; Department of Urology, Charité - University Medicine Berlin, Berlin, Germany.
  • Almedom Z; Department of Urology, Charité - University Medicine Berlin, Berlin, Germany.
  • Lichy I; Department of Urology, Charité - University Medicine Berlin, Berlin, Germany.
  • Buckendahl J; Department of Urology, Charité - University Medicine Berlin, Berlin, Germany.
  • Steiner U; Department of Urology, Charité - University Medicine Berlin, Berlin, Germany.
  • Friedersdorff F; Department of Urology, Charité - University Medicine Berlin, Berlin, Germany.
  • Busch J; Department of Urology, Charité - University Medicine Berlin, Berlin, Germany.
  • Fuller TF; Department of Urology, Charité - University Medicine Berlin, Berlin, Germany.
  • Miller K; Department of Urology, Charité - University Medicine Berlin, Berlin, Germany.
  • Hinz S; Department of Urology, Vivantes Klinikum am Urban, Berlin, Germany.
  • Cash H; Department of Urology, Charité - University Medicine Berlin, Berlin, Germany.
Urol Int ; 100(4): 463-469, 2018.
Article en En | MEDLINE | ID: mdl-29621785
ABSTRACT

PURPOSE:

The study aimed to evaluate progression of GreenLight-XPS 180 W photoselective vaporization of the prostate (GL-XPS) with respect to effectiveness, efficacy, and safety over time at a tertiary referral high volume center.

METHODS:

The retrospective study included 375 men who underwent GL-XPS for symptomatic benign prostate obstruction (BPO) between June 2010 and February 2015. Primary outcome measurements were operation time (OT; min) and effective laser time (LT; min of OT) analyzed with regard to prostatic volume (PV; mL) (group 1 <40 mL up to 4 >80 mL in 20 mL steps) and the year of surgery (2010-2015).

RESULTS:

The median age was 72 years (range 64-79), the median PV was 58 mL (range 33-98) and the median PV increased from 42 mL in 2012 to 80 mL in 2015. The OT and LT clearly correlated with the PV, being doubled for glands of median 95 mL compared to median 30 mL while the applied laser energy per LT likewise steadily increased. Overall, both OT and LT could be significantly reduced each year by 37% (OT; p < 0.05) and 36% (LT; p < 0.05) within 5 years. The hospital stay (days) and catheterization time (days) remained constant, without any changes over time. The overall complication rate (Clavien-Dindo >2) ranged from 36 to 15% between 2010 and 2015. The pre (median 22 + 4) and postoperative International Prostate Symptom Score-Quality of Life (median 5 + 1) showed a sufficient reduction in symptomatic BPO.

CONCLUSION:

GL-XPS is a safe and effective surgical method for symptomatic BPO. Our single center experience showed a significant improvement of both OT and effective LT within 5 years whilst maintaining stable low complication rate and high patient satisfaction.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Próstata / Hiperplasia Prostática / Terapia por Láser Tipo de estudio: Observational_studies Límite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Urol Int Año: 2018 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Próstata / Hiperplasia Prostática / Terapia por Láser Tipo de estudio: Observational_studies Límite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Urol Int Año: 2018 Tipo del documento: Article País de afiliación: Alemania